Cellectis (CLLS): 2017 Could Be The Transformative Year - Oppenheimer

September 14, 2016 7:47 AM EDT
Get Alerts CLLS Hot Sheet
Price: $18.53 +2.89%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 24 | New: 8
Trade CLLS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer analyst Michelle Gilson, reiterated her Outperform rating on shares of Cellectis (NASDAQ: CLLS) after the company Cellectis reported 2Q16 results that included €270M (US$303M) in cash, enough to to fund anticipated operations through YE2018. The anlalyst is focused UCART123 trials in AML and BPDCN which have YE2016/early-2017 trial starts, and initial data expected 2H17.

The analyst believes UCART19 (partnered with Servier/Pfizer) data from compassionate use program will be presented at ASH. Checks suggest multiple patients have been treated under compassionate use and early clinical data from the Phase 1 clinical study of UCART19 in pediatric B-ALL patients could also be presented at ASH, at the discretion of partners.

No change to the $65 PT.

price target of $65.00

For an analyst ratings summary and ratings history on Cellectis click here. For more ratings news on Cellectis click here.

Shares of Cellectis closed at $24.76 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment